Ampli1™ LowPass kit is designed to generate multiplexed, sequencing-ready libraries in a streamlined single-day protocol, to detect chromosomal aneuploidies and copy number aberrations (CNAs) by low-pass whole genome sequencing using Ion PGM™ and Ion S5™ systems.
Ampli1™ LowPass Kit product applications include the characterization and investigation of genomic heterogeneity and evolution in tumor cell populations such as individual circulating tumor cells (CTCs).
The Ampli1™ LowPass Kit works exclusively with Ampli1™ WGA products. The complete workflow takes advantage of the isolation of 100% pure cells with the DEPArray™ system and balanced whole genome amplification using the Ampli1™ WGA kit.
The quality of Ampli1™ WGA products can be assessed with Ampli1™ QC kit before proceeding with downstream library preparation and sequencing.
The Ampli1™ LowPass kit allows saving time compared to other procedures by avoiding the laborious fragmentation step and preparation of several enzyme reactions.
Performance of this method has been extensively validated by analyzing the Copy Number profiles of single CTCs and WBCs from cancer patients (see figure below for representative data).
Low-pass Whole Genome Profile (chr 1-22) of single CTC (upper panel) and WBC (lower panel) isolated with DEPArray Technology from a patient with Lung Adenocarcinoma. Ploidy values are indicated in the y-axis; in the x-axis the alternation of different chromosomes are plotted with different colors. Copy Number Alterations in the CTC are indicated in red and blue.
Ampli1™ LowPass Kit Key Features:
• Accurate characterization of CNA profiles of multiple single tumor cells per single run
• Up to 96 barcoded libraries
• Fast results (6h turnaround time for library preparation)
• Affordable cost for massively parallel single-cell analysis such as multiple tumor cells or CTCs
To download Material Safety Data Sheets (MSDS), please click here.
The Ampli1™ WGA Kit is for Research Use Only. Not for use in diagnostic procedures. Ampli1™ WGA Kits are protected by U.S. patent 6,673,541 and corresponding patent claims outside the United States.
